ACC pipeline
Studies
Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.
29 studies across 23 of 23 drugs. 29 studies are in the file.
Amivantamab1 study
- Amivantamab in ACCNCT05074940Phase 2Active, not recruitingn 21
Anlotinib + Epirubicin (neoadjuvant)1 study
- NAET4-SNACCNCT07616141Phase 2Recruitingn 76
Apatinib1 study
- NCT02775370NCT02775370Phase 2Unknown statusn 68
APG-115 (alrizomadlin)1 study
- NCT03781986NCT03781986Phase 1/2Active, not recruitingn 41
Axitinib (off Label)2 studies
- Axitinib vs observation (randomized Phase 2)NCT02859012Phase 2Completedn 60
- Axitinib + avelumab Phase 2 (MD Anderson)Registry id n/rPhase 2Completedn 40
CB-1032 studies
- CB-103 Phase 1/2 (terminated)NCT03422679Phase 1/2Terminatedn 79
- CB-103 + lenvatinib or abemaciclibNCT05774899Phase 1/2Recruitingn 32
Emiltatug Ledadotin (Emi-Le, XMT-1660)1 study
- Emi-Le Phase 1/2 (includes EMBLEM-1 pivotal cohort)NCT05377996Phase 1/2Recruitingn 360
Enfortumab Vedotin1 study
- NCT06891560NCT06891560Phase 2Recruitingn 34
HG1461 study
- HG146NCT06781567Phase 2Recruitingn 140
Ivonescimab1 study
- I-MACNCT06805617Phase 2Recruitingn 35
Lenvatinib (off Label)3 studies
- Lenvatinib MSK Phase 2NCT02780310Phase 2Active, not recruitingn 33
- ACC-LEN14NCT02860936Phase 2Completedn 26
- Lenvatinib + pembrolizumabNCT04209660Phase 2Active, not recruitingn 64
LUTETIUM-177 PSMA Radioligand2 studies
- LUPSANCT04291300Phase 2Completedn 12
- 177Lu-PNT2002 in ACC (terminated, n 1)NCT06322576Phase 2Terminatedn 1
NN32011 study
- NCT06805825NCT06805825Phase 1Recruitingn 67
Osugacestat (AL101, BMS-906024)1 study
- ACCURACYNCT03691207Phase 2Completedn 87
Puxitatug Samrotecan (P-Sam, AZD8205)1 study
- NCT07162480NCT07162480Phase 2Recruitingn 28
Regorafenib (off Label)1 study
- Regorafenib in ACCNCT02098538Phase 2Completedn 38
REM-4221 study
- ARIANCT06118086Phase 1/2Recruitingn 125
RGT-611592 studies
- RGT-61159 Phase 1a/bNCT06462183Phase 1Active, not recruitingn 105
- RGT-61159 Phase 3 (planned, not yet registered)Registry id n/rPhase 3Not yet recruitingn 150
Rivoceranib1 study
- Rivoceranib Phase 2NCT04119453Phase 2Terminatedn 80
Sacituzumab Tirumotecan (sac-TMT)1 study
- STRAPNCT07521670Phase 2Not yet recruitingn 68
SX-682 + Docetaxel1 study
- NCT07667400NCT07667400Phase 1/2Recruitingn 120
VMD-9281 study
- NCT03556228NCT03556228Phase 1/2Recruitingn 242
Zanzalintinib1 study
- ZANACCNCT07682675Phase 2Not yet recruitingn 51